Rhythm Biosciences Ltd. has announced an exploratory collaboration with datma, a leader in federated real-world data access, to evaluate how datma's federated data platform, datma.FED, can support and accelerate the commercialization of Rhythm's genomic-integrated cancer risk prediction portfolio. The partnership will focus on leveraging longitudinal, de-identified real-world clinical data to aid in the development of Rhythm's geneType™ risk assessment tool, supporting clinical utility evidence generation and health economic modelling. This collaboration aims to enhance the clinical relevance and adoption of population-based cancer risk stratification tools.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF52105) on December 22, 2025, and is solely responsible for the information contained therein.